ERBB2 and non-small cell lung carcinoma: It is also reported that cancer cells having HER2 mutations, present in a very small fraction of NSCLC, are insensitive to EGFR-TKI, but remain sensitive to HER2-targeted therapies (Wang et al, 2006).